Long term persistence with statin therapy: Experience in Australia 2006-2010

Australian Family Physician

Volumn 40, Issue 5, 2011, Pages 319-322

  Simons, Leon A ^a   Ortiz, Michael ^a,b   Calcino, Gordon ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Abbott Products Pty Ltd   (Australia)

^c HI Connections Pty Ltd   (Australia)

Author keywords

Hydroxymethylglutaryl Coa reductase inhibitors; Medication adherence

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; AUSTRALIA; FEMALE; HUMAN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; STATISTICS;

ADULT; AGED; AUSTRALIA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED;

EID: 79959572643     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Baigent C, Keech A, Kearney PM, et al, Cholesterol Treatment Trialists' (CT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
2. National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. Position statement on lipid management - 2005. Heart Lung Circ 2005;14:275-91.
3. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm2009;15:728-40.
4. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipidlowering drugs. Med J Aust 1996;164:208-11.
5. Simons LA, Simons J, McManus P, et al. Discontinuation rates for use of statins are high. BMJ 2000;321:1084.
6. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australiawide experience 2004-2006. Med J Aust 2008;188:224-7.
7. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications. A crossnational study. JAMA 1998;279:1458-62.
8. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
9. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
10. Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005;59:564-73.
11. Foody JM, Joyce AT, Rudolph AE, et al. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr Med Res Opin 2008;24:1987-2000.
12. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a notfor-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008;30:2167-79.
13. Helin-Salmivaara A, Lavikainen P, Korhonen MJ, et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther 2008;30:2228-40.
14. Kiortsis DN, Giral P, Bruckert E, et al. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000;25:445-51.
15. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52.
16. Perreault S, Blais L, Dragomir A, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005;61:667-74.
17. Robertson TA, Cooke CE, Wang J, et al. Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension. Am J Manag Care 2008;14:710-6.
18. Feyer A-M, Benrimoj SI, Schulman C, et al. National trial to test strategies to improve medication compliance in a community pharmacy setting. Pharmacy Guild of Australia 2010 Available at www.guild.org.au [Accessed 22 December 2010].
19. Lee JK, grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296:2563-71.
20. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence (review). Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD000011.
21. Drug Utilisation Sub-Committee (DUSC) of thePBAC. PBS Under Co-payment prescription data. Department of Health and Ageing 2010 (data available on request to Department).
22. Elliott WJ, Plauschinat CA, Skrepnek GH, et al. Persistence, adherence, and risk of discontinuation with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007;20:72-80.
23. Cherry SB, Benner JS, Hussein MA, et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value in Health 2009;12:489-97.
24. Nelson MR, Reid CM, Ryan P, et al. Self-reported adherence with medication and cardiovascular disease outcomes in the second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006;185:487-9.
25. Silva MA, Swanson AC, Gandhi PJ, et al. Statinrelated adverse events: a meta-analysis. Clin Ther 2006;28:26-35.
26. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed dose combinations of antihypertensive agents. A metaanalysis. Hypertension 2010;55:399-407.